Moleculin Biotech`s Annamycin has Fast Track Status and Orphan Drug Designation from FDA for the treatment of soft tissue sarcoma lung metastases.
the FDA agreed with Moleculin Biotech`s Investigational New Drug (IND) application to study WP1122 for the treatment of Glioblastoma Multiforme (GBM) to go forward.
This should be an interesting year for MBRX, which...
The Marketmiracle advisor reported last night a major entry on the stock $MBRX with a potential profit of 300% approximately
The company Moleculin Biotech has several active trials all in the field of cancer research and recently also against covid, has recently presented quarterly and annual data far above the expectations of analysts.
Recently a reverse split...
I think that $3 is the honey spot here. If it goes this low there will likely be a nice 100% gain. It will likely drop to some degree then make up for it in the short term.
Moleculin Announces 100% Survival Achieved in Osteosarcoma Lung Metastases Animal Model
a preclinical study in animals demonstrated a potentially significant therapeutic benefit of Annamycin against metastatic osteosarcoma.
Computerized tomography (CT) scans demonstrated that animals treated with Annamycin exhibited significant suppression of tumor growth and...
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066,...
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company, which focuses on the development of oncology drug candidates. Its Annamycin product candidate helps in the treatment of relapsed or refractory acute myeloid leukemia. The company's preclinical small molecule portfolios focus on the modulation of hard-to-target tumor cell signaling mechanisms and...
Saturday July 25th, 2020
• • • Disclaimer• • •
Please don't take this as a financial advice, remember I'm not a professional analytic,
this whole idea is based on my knowledge, interpretation and opinion. This is only my Idea,
don't buy or sell because of my idea. Do your own research in the company before deciding either buy...
Is $MBRX- The Best Biotech with the most upside Potential
Just announced a major breakthrough in its effort to develop a new cancer treatment that selectively kills highly resistant tumors. Company has a relatively small OS under 25 Mil and float under 15 Mil . The company is working with the most prestigious cancer centers to treat a broader range of the...
Nano cap Moleculin Biotech (MBRX +47.5%) rallies on a healthy 15x surge in volume in reaction to its agreement with the University of Texas Medical Branch at Galveston (UTMB) to conduct research on the company's line-up of molecular inhibitors, including lead candidate WP1122, to assess their antiviral properties against a range of viruses, including...
Set your alerts for this stock has a history of 100% spikes, price up premarket on no news?
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company, which focuses on the development of oncology drug candidates. Its Annamycin product candidate helps in the treatment of relapsed or refractory acute myeloid leukemia. The company's preclinical small...
Yesterdays gainers are quickly forgotten, up 170% on the 4/22/19 and loses drops 50% on 4/23/19 on news of new offering. Despite this a great opportunity may still exist in the name, tomorrow there is still scheduled call to announce developments in FDA approval and possible positive results from its new lung cancer drug.
Strong runner today off of some positive news, and the float sits just under 17M! I'll be watching this one for a possible continuation trade tomorrow!
